Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
Intellia Therapeutics (NTLA) Stock Price & Analysis
1,924 Followers
NTLA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$32.44 - $76.45
Previous Close$39.22
Volume769.19K
Average Volume (3M)1.11M
Market Cap
$3.44B
Enterprise Value$2.65B
Total Cash (Recent Filing)$933.54M
Total Debt (Recent Filing)$126.13M
Price to Earnings (P/E)-7.3
Beta2.25
Next Earnings
Aug 03, 2023EPS Estimate
-$1.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.39
Shares Outstanding88,140,978
10 Day Avg. Volume1,059,277
30 Day Avg. Volume1,109,524
Standard Deviation0.24
R-Squared0.17
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.09
Price to Sales (P/S)272.55
Price to Cash Flow (P/CF)-8.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue49.55
Enterprise Value/Gross Profit50.83
Enterprise Value/Ebitda-8.42
Forecast
1Y Price Target
$79.17Price Target Upside103.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Intellia Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $32.44 and its highest was $76.45 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Currently, no data Available
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Aug 03, 2023 which is in 68 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on May 04, 2023. The company reported -$1.17 earnings per share for the quarter, beating the consensus estimate of -$1.4 by $0.23.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -$1.32.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 88,140,976 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$1.17 in its last earnings report, beating expectations of -$1.4. Following the earnings report the stock price went up 13.142%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Among the largest hedge funds holding Intellia Therapeutics’s share is ARK Investment Management LLC. It holds Intellia Therapeutics’s shares valued at 367M.
---
Intellia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.17 (103.10% Upside)
$79.17 (103.10% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 92%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 565.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $47.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.39%
12-Months-Change
Fundamentals
Return on Equity
-40.14%
Trailing 12-Months
Asset Growth
17.88%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
---
Top 5 ETFs holding NTLA
ARK Genomic Revolution ETF
$78.23M
Vanguard Health Care ETF
$9.35M
iShares NASDAQ US Biotechnology UCITS ETF
$1.84M
Fidelity MSCI Health Care Index ETF
$1.64M
Vanguard ESG U.S. Stock ETF
$668.13K
Up to five ETFs with an Outperform Smart Score that hold NTLA. The ETFs are listed according to market value of NTLA within the ETF
---
---